Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
Adult Atypical Sporadic Burkitt Lymphoma successfully treated with Bendamustine and Rituximab. One combination for stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL), with or without prior rituximab-containing chemoimmunotherapy treatment, is bendamustine with mitoxantrone and rituximab. [7]
Twenty dangerous opioids and drugs will be banned in a new crackdown announced by the Home Office.. The ban will see 15 new dangerous synthetic opioids and five other drugs become Class A drugs ...
Idelalisib is a second-line medication for people whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab, [9] idelalisib is to be used in people for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions. [9]
When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; citabine - an antimetabolite; aliplatin - a platinum-based alkylating antineoplastic agent. [1] [2]
Blinatumomab linking a T cell to a malignant B cell.. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.